You are responsible for the videos uploaded to the Health Care instance of Media Space, This instance is meant to be a public library of videos. Content should not contain PHI or private information.
In Spring 2022, the FDA approved tirzepatide to help control insulin for patients with Type 2 Diabetes. Yet news stories were more focused on a secondary effect of the drug, known by the brand name Mounjaro™️: significant weight loss with just a weekly injection. Juliana Simonetti, MD, co-director of the Comprehensive Weight Management Program at University of Utah Health, explains how this new drug works and its potential for weight management if it were to be approved for that use.